Incyte Co. (NASDAQ:INCY) Shares Acquired by Bellevue Group AG

Bellevue Group AG increased its stake in shares of Incyte Co. (NASDAQ:INCY) by 0.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,157,478 shares of the biopharmaceutical company’s stock after purchasing an additional 6,927 shares during the period. Incyte accounts for about 2.9% of Bellevue Group AG’s holdings, making the stock its 12th biggest position. Bellevue Group AG owned about 1.12% of Incyte worth $149,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWA Asset Management Group LLC acquired a new position in shares of Incyte in the fourth quarter worth $1,933,000. Wells Fargo & Company MN raised its stake in Incyte by 61.3% in the 4th quarter. Wells Fargo & Company MN now owns 174,190 shares of the biopharmaceutical company’s stock valued at $12,031,000 after purchasing an additional 66,220 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in Incyte in the 4th quarter valued at about $1,006,000. JPMorgan Chase & Co. boosted its stake in shares of Incyte by 13.5% during the 4th quarter. JPMorgan Chase & Co. now owns 323,640 shares of the biopharmaceutical company’s stock worth $22,354,000 after purchasing an additional 38,550 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Incyte by 262.2% during the fourth quarter. SG Americas Securities LLC now owns 99,407 shares of the biopharmaceutical company’s stock worth $6,866,000 after buying an additional 71,963 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on INCY. JMP Securities restated a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Wells Fargo & Company upped their target price on Incyte from $58.00 to $59.00 and gave the company an “equal weight” rating in a research note on Wednesday. JPMorgan Chase & Co. decreased their price target on Incyte from $70.00 to $68.00 and set a “neutral” rating on the stock in a research note on Monday, April 21st. William Blair downgraded shares of Incyte from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 18th. Finally, Stifel Nicolaus raised their target price on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, February 10th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $73.53.

Incyte Trading Up 0.8 %

NASDAQ:INCY opened at $62.53 on Friday. The business’s 50-day moving average is $62.53 and its two-hundred day moving average is $68.87. The firm has a market capitalization of $12.10 billion, a PE ratio of 231.60, a price-to-earnings-growth ratio of 0.41 and a beta of 0.68. Incyte Co. has a 12 month low of $52.81 and a 12 month high of $83.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating the consensus estimate of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $996.17 million. During the same period last year, the business posted $0.64 EPS. The company’s revenue was up 19.5% on a year-over-year basis. Research analysts predict that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the transaction, the executive vice president now owns 33,567 shares of the company’s stock, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,475 shares of company stock valued at $2,424,751 in the last ninety days. Insiders own 17.60% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.